Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 8 trials

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total

P 2 (5)

P 3 (2)

Trial Status

Unknown4

Not Yet Recruiting2

Recruiting2

Clinical Trials (8)

Showing 8 of 8 trials

NCT07506109Phase 2Not Yet Recruiting

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

NCT06616259Phase 3Not Yet Recruiting

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

NCT05022030Phase 2Recruiting

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

NCT04923620Recruiting

Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

NCT06101394Phase 2Unknown

Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules

NCT06118047Phase 2Unknown

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab

NCT04136600Phase 2Unknown

EGFR Monoclonal Antibody for Advanced Gastric Cancer

NCT04509635Phase 3Unknown

Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis